Georgetown University

CytoDyn has dosed the first patient in a Phase II clinical trial evaluating leronlimab, a CCR5 antagonist, in patients with relapsed/refractory microsatellite stable colorectal cancer.

Georgetown University and MedStar Health researchers developed a blood test that uses circulating cell-free DNA fragments to detect early signs of liver transplant rejection and complications.

TG01 cancer vaccine demonstrated excellent safety profile and induced mutant RAS-specific T-cell responses in 50% of multiple myeloma patients in a phase 1/2 trial.

A randomized controlled trial of 136 Latina breast cancer survivor-caregiver pairs demonstrated high engagement rates, with 71.4% attending at least five of eight intervention sessions and 82% retention at six months.

Immorta Bio's SenoVax, a first-in-class senolytic immunotherapy, demonstrated regression of brain, lung, skin, pancreas, and breast cancers in animal models by targeting senescent cells that protect tumors from immune attack.

• A phase 2 trial of nilotinib in patients with Dementia with Lewy Bodies (DLB) showed promising cognitive benefits over a 6-month period. • Patients treated with nilotinib demonstrated a statistically significant improvement on the Alzheimer’s Disease Assessment Scale-Cognition 14. • The study reported that nilotinib was safe and well-tolerated, with fewer adverse events compared to the placebo group. • Nilotinib's mechanism involves inducing autophagy and reducing inflammation in the brain, potentially addressing both cognitive and motor symptoms of DLB.

The Biden administration's Medicare drug price negotiation program, established through the Inflation Reduction Act, faces potential changes under a Trump presidency, though complete repeal appears politically challenging.

STEMCELL Technologies, Canada's largest biotechnology company, acquired substantially all assets of SQZ Biotechnologies for $400+ million, gaining access to mechanoporation technology and over 400 patents for cell therapy delivery applications.